Identifying a therapeutic target for ganciclovir against cytomegalovirus in immunocompromised children
A serum GCV AUC<sub>24h</sub> target of 40-100 mg/L·h may serve as a preliminary reference for the treatment of CMV infection in immunocompromised children. Notably, the therapeutic target is affected by the individual's immune status.
Authors
- Brett C McWhinney (ORCID: https://orcid.org/0000-0001-9632-1148)
- Theresa S. Cole (ORCID: https://orcid.org/0000-0002-8272-4074)
- Xiao Zhu (ORCID: https://orcid.org/0000-0003-3295-619X)
- Amanda Gwee (ORCID: https://orcid.org/0000-0003-4016-8986)
- Heather Weerdenburg (ORCID: https://orcid.org/0000-0002-8592-4311)
- Wenyu Yang (ORCID: https://orcid.org/0000-0002-9057-4520)
- Adam Irwin (ORCID: https://orcid.org/0000-0001-8974-6789)
- Alice Lei (ORCID: https://orcid.org/0009-0004-2404-4830)
Institutions
- Royal Children's Hospital (AU)
- The University of Queensland (AU)
- The University of Melbourne (AU)
- Fudan University (CN)
- Royal Brisbane and Women's Hospital (AU)
- Murdoch Children's Research Institute (AU)
- Children's Health Queensland Hospital and Health Service (AU)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1002/bcp.70315
- Citations
- 1
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 1.35